Concomitant therapy with the following medications was prohibited: other ARBs, angiotensin-converting enzyme (ACE) inhibitors, β-adrenergic antagonists, calcium-channel blockers, any other ...

Morning hypertension has been reported to be an important risk factor for cardiovascular events, and arterial stiffness bears a relationship with cardiovascular risk. The aim of this study was to ...

The results of the Valsartan/HCTZ Combination Therapy in Patients With Moderate to Severe Systolic Hypertension (VALOR) study [1] show that valsartan 160 mg once daily is safe and effective in older ...

The new year brings a new blood pressure medication recall. This time Aurobindo Pharma USA has recalled 80 lots of its Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets USP and Valsartan ...

Angiotensin II, the principal effector peptide of the renin-angiotensin-aldosterone system (RAAS), has potent vasoconstrictive and other effects that can lead to cardiac and renal complications.

Earlier this month, the FDA announced a voluntary recall of some valsartan-containing drugs after N-nitrosodimethylamine (NDMA) was found in the active pharmaceutical ingredients (API) manufactured by ...

Please provide your email address to receive an email when new articles are posted on . Declines in estimated glomerular filtration rate after transition to sacubitril/valsartan for HF are mild and ...

Amlodipine (as besylate) 5 mg, valsartan 160 mg; tabs. Exforge combines two antihypertensive drugs that have complementary mechanisms of action: amlodipine, a calcium (Ca+) channel blocker, and ...

This study evaluated levels of 4 biomarkers associated with heart failure with reduced ejection fraction (HFrEF) before and after treatment with the angiotensin receptor neprilysin inhibitor ...